With a new FDA Commissioner announced in August and “micro” trends at the FDA continuing to shift every two to three months, this presentation tracks recent and rapidly evolving developments from peptides to tariffs. The discussion will evaluate where the agency stands today and what to watch considering the risks and opportunities likely to shape the life sciences industry in the coming months.
Speakers:
- Dominick DiSabatino, Partner, Sheppard
- Scott Liebman, Partner, Sheppard